Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY: TBAJ-587 combination regimens in newly diagnosed drug-sensitive pulmonary tuberculosis
PACTR202609559047245Phase 2Not yet recruiting
- Sponsor
- TASK Foundation
- Start
- Aug 2026
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of TBAJ-587 in pulmonary tuberculosis (TB) (6 arms), sponsored by TASK Foundation. Primary endpoint: Rate of change in log10(TTP) in sputum over the period 0 to 8 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
TBAJ-587
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202609559047245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202609559047245.